Draflazine | CAS#120770-34-5 | nucleoside transport inhibitor

MedKoo Cat#: 461086 | Name: Draflazine

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Draflazine is a nucleoside transport inhibitor.

Chemical Structure

Draflazine

CAS#120770-34-5

Theoretical Analysis

MedKoo Cat#: 461086

Name: Draflazine

CAS#: 120770-34-5

Chemical Formula: C30H33Cl2F2N5O2

Exact Mass: 603.1979

Molecular Weight: 604.52

Elemental Analysis: C, 59.61; H, 5.50; Cl, 11.73; F, 6.29; N, 11.59; O, 5.29

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

Draflazine; R 75231; R-75231; R75231;

IUPAC/Chemical Name

(S)-1-(2-((4-amino-2,6-dichlorophenyl)amino)-2-oxoethyl)-4-(5,5-bis(4-fluorophenyl)pentyl)piperazine-2-carboxamide

InChi Key

IWMYIWLIESDFRZ-MHZLTWQESA-N

InChi Code

InChI=1S/C30H33Cl2F2N5O2/c31-25-15-23(35)16-26(32)29(25)37-28(40)18-39-14-13-38(17-27(39)30(36)41)12-2-1-3-24(19-4-8-21(33)9-5-19)20-6-10-22(34)11-7-20/h4-11,15-16,24,27H,1-3,12-14,17-18,35H2,(H2,36,41)(H,37,40)/t27-/m0/s1

SMILES Code

Fc1ccc(C(c2ccc(F)cc2)CCCCN3CCN([C@H](C(N)=O)C3)CC(Nc4c(Cl)cc(N)cc4Cl)=O)cc1

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.03.00

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 604.52 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Snoeck E, Piotrovskij V, Jacqmin P, Lins RL, Van Peer A, Danhof M, Woestenborghs R, Van Gool R, Dupont AG, Heykants J. Population analysis of the non-linear red blood cell partitioning of draflazine following various infusion durations. Eur J Clin Pharmacol. 1997;53(1):57-63. PubMed PMID: 9349931. 2: Hammond JR. Interaction of a series of draflazine analogues with equilibrative nucleoside transporters: species differences and transporter subtype selectivity. Naunyn Schmiedebergs Arch Pharmacol. 2000 Apr;361(4):373-82. PubMed PMID: 10763851. 3: Andersen K, Dellborg M, Swedberg K. Nucleoside transport inhibition by draflazine in unstable coronary disease. Eur J Clin Pharmacol. 1996;51(1):7-13. PubMed PMID: 8880045. 4: Snoeck E, Jacqmin P, Van Peer A, Danhof M. A combined specific target site binding and pharmacokinetic model to explore the non-linear disposition of draflazine. J Pharmacokinet Biopharm. 1999 Jun;27(3):257-81. PubMed PMID: 10728489. 5: Snoeck E, Piotrovskij V, Jacqmin P, Van Peer A, Danhof M, Ver Donck K, Woestenborghs R, Van Belle H, Van Bortel L, Van Gool R, Dupont AG, Heykants J. Population analysis of the non linear red blood cell partitioning and the concentration-effect relationship of draflazine following various infusion rates. Br J Clin Pharmacol. 1997 Jun;43(6):603-12. PubMed PMID: 9205820; PubMed Central PMCID: PMC2042791. 6: Snoeck E, Jacqmin P, Van Peer A, Danhof M, Ver Donck K, Van Belle H, Woestenborghs R, Crabbé R, Van Gool R, Dupont A, Heykants J. The implications of non-linear red blood cell partitioning for the pharmacokinetics and pharmacodynamics of the nucleoside transport inhibitor draflazine. Br J Clin Pharmacol. 1996 Nov;42(5):605-13. PubMed PMID: 8951192. 7: Rongen GA, Smits P, Bootsma G, Ver Donck K, de Vries A, Thien T. High-grade nucleoside transport inhibition stimulates ventilation in humans. J Clin Pharmacol. 1995 Apr;35(4):357-61. PubMed PMID: 7650223. 8: Böhm M, Weinhold C, Schwinger RH, Müller-Ehmsen J, Böhm D, Reichenspurner H, Reichart B, Erdmann E. Studies of the nucleoside transporter inhibitor, draflazine, in the human myocardium. Br J Pharmacol. 1994 May;112(1):137-42. PubMed PMID: 8032635; PubMed Central PMCID: PMC1910273. 9: Rongen GA, Lenders JW, Lambrou J, Willemsen JJ, Van Belle H, Thien T, Smits P. Presynaptic inhibition of norepinephrine release from sympathetic nerve endings by endogenous adenosine. Hypertension. 1996 Apr;27(4):933-8. PubMed PMID: 8613271. 10: Snoeck E, Ver Donck K, Jacqmin P, Van Belle H, Dupont AG, Van Peer A, Danhof M. Physiological red blood cell kinetic model to explain the apparent discrepancy between adenosine breakdown inhibition and nucleoside transporter occupancy of draflazine. J Pharmacol Exp Ther. 1998 Jul;286(1):142-9. PubMed PMID: 9655853. 11: Dennis DM, Raatikainen MJ, Martens JR, Belardinelli L. Modulation of atrioventricular nodal function by metabolic and allosteric regulators of endogenous adenosine in guinea pig heart. Circulation. 1996 Nov 15;94(10):2551-9. PubMed PMID: 8921800. 12: Fong M, Yoshitake M, Kambayashi J, Liu Y. Cilostazol increases tissue blood flow in contracting rabbit gastrocnemius muscle. Circ J. 2010 Jan;74(1):181-7. Epub 2009 Dec 5. PubMed PMID: 19966507. 13: Beukers MW, Kerkhof CJ, IJzerman AP, Soudijn W. Nucleoside transport inhibition and platelet aggregation in human blood: R75231 and its enantiomers, draflazine and R88016. Eur J Pharmacol. 1994 Jan 1;266(1):57-62. PubMed PMID: 8137884. 14: Zhang H, De Jongh R, Cherkaoui S, Shahram M, Vray B, Vincent JL. Effects of nucleoside transport inhibition on hepatosplanchnic perfusion, oxygen extraction capabilities, and TNF release during acute endotoxic shock. Shock. 2001 May;15(5):378-85. PubMed PMID: 11336198. 15: Ottervanger JP, Gregor P, Widimsky P, Zijlstra F, Kluiver EP, Hof AW, Suryapranata H. Cardioprotective effects of adenosine transport inhibition during reversible ischaemia in patients with coronary artery disease. Int J Cardiovasc Intervent. 1999;2(3):181-186. PubMed PMID: 12623587. 16: Sommerschild HT, Grund F, Offstad J, Jynge P, Ilebekk A, Kirkebøen KA. Importance of endogenous adenosine during ischemia and reperfusion in neonatal porcine hearts. Circulation. 1997 Nov 4;96(9):3094-103. PubMed PMID: 9386180. 17: Rongen GA, Smits P, Ver Donck K, Willemsen JJ, De Abreu RA, Van Belle H, Thien T. Hemodynamic and neurohumoral effects of various grades of selective adenosine transport inhibition in humans. Implications for its future role in cardioprotection. J Clin Invest. 1995 Feb;95(2):658-68. PubMed PMID: 7860749; PubMed Central PMCID: PMC295532. 18: Maes SS, Pype S, Hoffmann VL, Biermans M, Meert TF. Antihyperalgesic activity of nucleoside transport inhibitors in models of inflammatory pain in guinea pigs. J Pain Res. 2012;5:391-400. doi: 10.2147/JPR.S35108. Epub 2012 Oct 12. PubMed PMID: 23091396; PubMed Central PMCID: PMC3474157. 19: Sommerschild HT, Lunde PK, Deindl E, Jynge P, Ilebekk A, Kirkebøen KA. Elevated levels of endogenous adenosine alter metabolism and enhance reduction in contractile function during low-flow ischemia: associated changes in expression of Ca(2+)-ATPase and phospholamban. J Mol Cell Cardiol. 1999 Oct;31(10):1897-911. PubMed PMID: 10525427. 20: Kollias-Baker C, Xu J, Pelleg A, Belardinelli L. Novel approach for enhancing atrioventricular nodal conduction delay mediated by endogenous adenosine. Circ Res. 1994 Dec;75(6):972-80. PubMed PMID: 7955151.